Sign In
Buy SYRE
$98.33
-3.17 (-3.12%)
At Close: Jul 31, 2026
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares
06:15am, Monday, 06'th Apr 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average pric
Scott Burrows Sells 7,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock
05:56am, Sunday, 05'th Apr 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) CFO Scott Burrows sold 7,500 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $49.34,
Spyre Therapeutics Announces Grants of Inducement Awards
04:01pm, Friday, 03'rd Apr 2026
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools
10:34pm, Wednesday, 18'th Mar 2026
VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 mil
Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms
02:18pm, Tuesday, 17'th Mar 2026
Spyre Therapeutics, Inc. receives a Strong Buy rating, driven by positive phase 1 data and robust pipeline progress in IBD and rheumatic diseases. SPY001 demonstrated a half-life 4x greater than ENTYV
Spyre Therapeutics, Inc. $SYRE Shares Bought by B Group Inc.
03:07am, Saturday, 14'th Mar 2026
B Group Inc. increased its holdings in Spyre Therapeutics, Inc. (NASDAQ: SYRE) by 25.0% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 100,000 shares of
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript
01:40am, Wednesday, 11'th Mar 2026
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript
Spyre Therapeutics Announces Grants of Inducement Awards
04:05pm, Friday, 06'th Mar 2026
WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
04:05pm, Tuesday, 24'th Feb 2026
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefin
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
04:02pm, Thursday, 19'th Feb 2026
On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second
Spyre Therapeutics Announces Grants of Inducement Awards
04:01pm, Friday, 06'th Feb 2026
WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies a
Short Interest in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Drops By 13.5%
01:20am, Thursday, 05'th Feb 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 10,069,741 sha
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages
04:09am, Monday, 02'nd Feb 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) has received an average rating of "Buy" from the ten brokerages that are presently covering the firm, MarketBeat.com reports. One research ana
Spyre Therapeutics Announces Grants of Inducement Awards
04:00pm, Friday, 23'rd Jan 2026
WALTHAM, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies a
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
08:00am, Monday, 12'th Jan 2026
“6 in '26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment comple
